Metallic radionuclides: Applications in diagnostic and therapeutic nuclear medicine

被引:0
|
作者
Weiner, RE [1 ]
Thakur, ML [1 ]
机构
[1] THOMAS JEFFERSON UNIV HOSP, DIV NUCL MED, PHILADELPHIA, PA 19107 USA
关键词
nuclear medicine; radiopharmaceuticals; In-111; Ga-67; (TI)-T-201; Sr-89;
D O I
暂无
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Nuclear Medicine is a medical modality that utilizes radioactivity (radiopharmaceutical) to diagnose and treat disease. Radiopharmaceuticals contain a component which directs the radionuclide to the desire physiological target. For diagnostic applications, these nuclides must emit a gamma ray that can penetrate the body and can be detected externally while for therapeutic purposes nuclides are preferred that emit beta particles and deliver highly localized tissue damage. Ga-67 citrate is employed to detect chronic occult abscesses, Hodgkin's and non-Hodgkin's lymphomas, lung cancer, hepatoma and melanoma and localizes in these tissues utilizing iron-binding proteins. (201)Thallous chloride, a potassium analogue, used to diagnosis coronary artery disease, is incorporated in muscle tissue via the Na+-K+-ATPase. In-111 labeled autologous white blood cells, used for the diagnosis of acute infections and inflammations,takes advantage of the white cell's role in fighting infections. (111)Ln is incorporated in other radiopharmaceuticals e.g. polyclonal Igc, OncoScint CR/OV, OctreoScan and Myoscint by coupling diethylenetriaminepentaacetic acid, a chelate, covalently to these molecules. OncoScint CR/OV and Myoscint localize by antigen antibody interactions while OctreoScan is taken up by malignant cells in a receptor based process. Polyclonal IgG may share some localization characteristics with Ga-67. Sr-89, a pure beta emitter, is used for palliation of bone pain due to metastatic bone lesions. Bone salts [Ca(PO)(4)] are increased in these lesions and this radionuclide is taken up similarly to Ca2+. Re-186 and Sm-153 bound to polydentate phosphonate chelates are used similarly and follow the phosphate pathway in lesion incorporation.
引用
收藏
页码:273 / 287
页数:15
相关论文
共 50 条
  • [31] Reactor production and processing of therapeutic radioisotopes for applications in nuclear medicine
    Knapp, FF
    Beets, SMAL
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY-ARTICLES, 1996, 205 (01): : 93 - 100
  • [32] Novel thymidine analogs as potential diagnostic and therapeutic agents in nuclear medicine
    Bartholomae, Mark D.
    Zubieta, Jon A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [33] Modern Technologies for Producing Radionuclides for Nuclear Medicine
    Zherebchevsky V.I.
    Alekseev I.E.
    Maltsev N.A.
    Petrov V.V.
    Prokofiev N.A.
    Zemlin E.O.
    Torilov S.Y.
    Bulletin of the Russian Academy of Sciences: Physics, 2023, 87 (08) : 1207 - 1216
  • [34] Nuclear data for production of therapeutic radionuclides.
    Nortier, FM
    Betak, E
    Noy, RC
    Carlson, BV
    Choi, HD
    Qaim, SM
    De Corcuera, RP
    Shubin, YN
    Sublet, JC
    Tarkanyi, TF
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U308 - U308
  • [36] A background to nuclear transfer and its applications in agriculture and human therapeutic medicine
    Campbell, KHS
    JOURNAL OF ANATOMY, 2002, 200 (03) : 267 - 275
  • [37] RADIATION BIOLOGY AND POTENTIAL THERAPEUTIC APPLICATIONS OF RADIONUCLIDES
    HOFER, KG
    BULLETIN DU CANCER, 1980, 67 (03) : 343 - 353
  • [38] SPECIFIC ACTIVITY OF URINE EXCRETED BY NUCLEAR-MEDICINE DIAGNOSTIC AND THERAPEUTIC PATIENTS
    ALLAN, MD
    BOYLES, JM
    HEALTH PHYSICS, 1980, 39 (06): : 1023 - 1023
  • [39] Neutron-activated theranostic radionuclides for nuclear medicine
    Tan, Hun Yee
    Yeong, Chai Hong
    Wong, Yin How
    McKenzie, Molly
    Kasbollah, Azahari
    Shah, Mohamad Nazri Md
    Perkins, Alan Christopher
    NUCLEAR MEDICINE AND BIOLOGY, 2020, 90-91 : 55 - 68